debt
confidence high
sentiment neutral
materiality 0.40
Hepion Pharmaceuticals issues $500K secured convertible note to Gravitas Capital
Hepion Pharmaceuticals, Inc.
- $500,000 secured convertible note with 8% paid-in-kind interest, maturing Sept 3, 2027.
- Note convertible at $0.04/share, contingent on stockholder approval to increase authorized shares.
- Warrant to buy 12.5M common shares at $0.06, exercisable until Sept 3, 2031.
- Note secured by all company assets; sale is unregistered under Regulation D/4(a)(2).